RBC Capital Maintains Outperform on Elevance Health, Raises Price Target to $574
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Ben Hendrix has maintained an Outperform rating on Elevance Health (NYSE:ELV) and increased the price target from $572 to $574.
January 25, 2024 | 4:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Ben Hendrix reaffirmed an Outperform rating on Elevance Health and raised the price target to $574.
The increase in price target by RBC Capital suggests a positive outlook on Elevance Health's performance, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100